>欧洲药物辅助治疗 (MAT) 市场，按类型（药物和疗法）、产品（丁丙诺啡和纳洛酮、纳曲酮、丁丙诺啡、美沙酮、纳洛酮、双硫仑和阿坎酸）、药物类型（仿制药和品牌药）、剂型（速释剂和缓释剂）、给药途径（口服、肠胃外和其他）、人群类型（成人和青少年）、最终用户（康复诊所、医院、专科中心、家庭护理和其他）分销渠道（医院药房、直接招标、零售药房、网上药房和其他）、行业趋势和预测到 2029 年
市场分析和见解
美国食品药品管理局（FDA）批准了三种临床药物：丁丙诺啡、美沙酮和纳曲酮。药物辅助治疗（MAT）用于治疗酒精使用障碍、阿片类药物依赖药物和阿片类药物过量预防药物。酒精使用障碍（AUD）是一种疾病，其特征是尽管对社会、职业或健康有不良影响，但仍无法停止饮酒。阿坎酸、双硫仑和纳曲酮是治疗酒精使用障碍（AUD）的最常见药物。阿片类药物依赖药物导致患者对阿片类药物的依赖性增加。丁丙诺啡、美沙酮和纳曲酮用于治疗阿片类药物使用障碍，包括短效阿片类药物，如海洛因、吗啡和可待因，以及半合成阿片类药物，如羟可酮和氢可酮。这些 MAT 药物可以安全使用数月、数年甚至一生。
市场定义
药物辅助治疗 (MAT) 涉及使用药物，结合咨询和行为疗法，为治疗物质使用障碍提供完整的患者治疗方法。MAT 的目的是适当的恢复，包括提高患者生存率、增加治疗保留率、减少非法反应和提高女性的妊娠结果。对于阿片类药物过量预防药物，纳洛酮用于通过逆转过量服用的毒性作用来预防阿片类药物过量。根据世界卫生组织 (WHO) 和药物滥用和精神健康服务管理局 (SAMHSA) 的说法，纳洛酮是许多被认为对正常运作的医疗保健系统至关重要的药物之一。欧洲药物辅助治疗是支持性的，旨在减轻症状的严重程度。Data Bridge Market Research 分析称，从 2022 年到 2029 年，药物辅助治疗 (MAT) 市场将以 8.7% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others) |
|
Countries Covered |
Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and Rest of Europe. |
|
Market Players Covered |
Indivior PLC, Alkermes. Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Pfizer Inc., Accord Healthcare (A subsidiary of Intas Pharmaceuticals), Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. |
Europe Medication-Assisted Treatment (MAT) Market Dynamics
Drivers
- . The Rise In Incidence Of Opioid Use Disorders (Opioid Dependency Medication)
Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to provide a "whole-patient" approach to treating substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA), and MAT programs are clinically driven and tailored to meet each patient's needs.
For instance,
- The prevalence of high-risk opioid use (by injection or long duration/regular use) among adults (aged 15–64) in Europe has been relatively stable for many years, with estimates of users standing at around 0.35 % of the EU population
As the companies are constantly engaged in research and developmental activities, the knowledge about the incidence of alcohol use disorder and opioid use disorders would help in finding novel solutions and that would aid in more collaborations and partnerships with market players in countries such as the U.S., Europe, and Asia-Pacific region. This signifies the increase in research and development-related investments for initiating generic medications in medication-assisted treatment (MAT), which is expected to boost the market growth.
- The Funding By The Government For Medication-Assisted Treatment (MAT)
Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to implementing medications for addiction treatment (MAT) by specialty treatment programs have been observed. Particular attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries.
For instance,
- In February 2021, the Integrated Substance Use Disorder Training Program (ISTP) was funded to plan, develop, and operate a 12-month full-time or 24-month half-time training program for nurse practitioners and physician assistants for medication-assisted treatment (MAT). The funding expands the workforce trained to provide care for individuals in need of mental health and opioid use disorder prevention
The funding by the government would result in the patient's safety, and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.
Opportunity
- Rise In Healthcare Expenditure
Moreover, the rise in the research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.
For instance,
- In December 2021, according to Eurostat, the health expenditure in the European Union amounted to USD 1,309.6 million
Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favourable factor. The above are expected to create lucrative opportunities for the medication-assisted treatment (MAT) market.
Restraint/Challenge
- Stringent Regulations
The companies must carefully review the product specifications and certifications before categorizing their product according to the Food and Drug Administration (FDA) and the European Union (EU). Every country has its regulatory authority responsible for enforcing rules and regulations for drug development, licensing, registration, manufacturing, marketing, and labelling pharmaceutical products.
For instance,
- In Germany, the Federal government, the Medicines and Healthcare products Regulatory Agency (MHRA), regulates and provides guidelines for the treatment of alcohol disorder and opioid overdose disorder when medication-assisted treatment (MAT) is considered to be a medicinal product (MP), for quality and safety (Q and S) testing regulations
Regulators need to work more closely with scientists, and even if they are involved in commercial enterprises, Regulatory agencies need to work more rapidly and efficiently on the processing and approve of everything they regulate. Manufacturers have to ensure that they have the entire product efficacy data performed before submitting product approval applications to regulatory authorities. Hence, a strict regulatory framework causes late product launches in the market. This implies that the rigid regulatory framework is expected to act as a challenge to market growth.
The medication-assisted (MAT) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on medication-assisted treatment (MAT) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on the Medication-Assisted (MAT) Treatment Market
During the pandemic, medication-assisted treatment remarkably reduces mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for medication-assisted treatment in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during Covid-19 Medication for opioid use disorder (MOUD) services are key to addressing the opioid crisis, and COVID-19 has significantly impacted MOUD delivery.
Recent Development
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
Europe Medication-Assisted Treatment (MAT) Market Scope
The medication-assisted treatment (MAT) market is segmented on the basis of eight segments: type, products, drug type, and dosage form, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Medication
- Therapy
On the basis of type the Europe medication-assisted treatment (MAT) market is segmented into medication and therapy.
Products
- Buprenorphine and Naloxone
- Naltrexone
- Buprenorphine
- Methadone
- Naloxone
- Disulfiram
- Acamprosate
On the basis of products, the Europe medication-assisted treatment (MAT) market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, methadone, naloxone, disulfiram and acamprosate.
Drug Type
- Generics
- Branded
On the basis of drug type, the Europe medication-assisted treatment (MAT) market is segmented into generics and branded.
Dosage Form
- Immediate Release
- Extended Release
On the basis of dosage form, the Europe medication-assisted treatment (MAT) market is segmented into immediate release and extended release.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the Europe medication-assisted treatment (MAT) market is segmented into oral, parenteral and others.
Population Type
- Adults
- Teenage
On the basis of population type, the Europe medication-assisted treatment (MAT) market is segmented into adults and teenage.
End User
- Rehabilitation Clinics
- Hospitals
- Specialty Centers
- Homecare
- Others
On the basis of end user, the Europe medication-assisted treatment (MAT) market is segmented into rehabilitation clinics, hospitals, speciality centers, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Direct Tender
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the Europe medication-assisted treatment (MAT) market is segmented into hospital pharmacy, direct tender, retail pharmacy, online pharmacy and others
Medication-Assisted Treatment (MAT) Market Regional Analysis/Insights
The Europe medication-assisted treatment (MAT) market is analysed and market size insights and trends are provided by regions, product type, type, application, workflow, end user and distribution channel as referenced above.
The countries covered in the medication-assisted treatment (MAT) market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and the rest of Europe.
Germany is expected to dominate the market due to the presence of rehabilitation centres for MAT, the rise in reimbursement, and the rise of pharmaceutical companies.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Medication-Assisted Treatment (MAT) Market Share Analysis
欧洲药物辅助治疗 (MAT) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对药物辅助 (MAT) 治疗市场的关注有关。
药物辅助治疗 (MAT) 市场的一些主要参与者包括 Indivior PLC、Alkermes、Sun Pharmaceutical Industries Ltd.、Taj Pharmaceuticals Limited、Hikma Pharmaceuticals PLC、Pfizer Inc.、Accord Healthcare（Intas Pharmaceuticals 的子公司）、Glenmark Pharmaceutical Inc. Viatris Inc.、Mallinckrodt、Alvogen、Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL
4.3 PORTER'S FIVE FORCES MODEL
4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021)
4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021)
4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021)
4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021)
4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET
5 EUROPE MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS
6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT)
6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.2 RESTRAINTS
6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT)
6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT)
6.2.3 RISE IN PRODUCT RECALLS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE
6.4 CHALLENGES
6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT
6.4.2 STRINGENT REGULATIONS
6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT)
7 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 OPIOID DEPENDENCY MEDICATION
7.2.1.1 BUPRENORPHINE AND NALOXONE
7.2.1.2 BUPRENORPHINE
7.2.1.3 METHADONE
7.2.1.4 NALTREXONE
7.2.2 ALCOHOL USE DISORDER MEDICATIONS
7.2.2.1 NALTREXONE
7.2.2.2 DISULFIRAM
7.2.2.3 ACAMPROSATE
7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION
7.2.3.1 NALOXONE
7.3 THERAPY
7.3.1 BEHAVIORAL THERAPY
7.3.2 EDUCATIONAL THERAPY
7.3.3 COUNSELLING
7.3.4 VOCATIONAL THERAPY
7.3.5 OTHERS
8 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS
8.1 OVERVIEW
8.2 BUPRENORPHINE AND NALOXONE
8.3 NALTREXONE
8.4 BUPRENORPHINE
8.5 METHADONE
8.6 NALOXONE
8.7 DISULFIRAM
8.8 ACAMPROSATE
9 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 GENERICS
9.3 BRANDED
9.3.1 SUBOXONE
9.3.2 VIVITROL
9.3.3 BUTRANS
9.3.4 ZUBSOLV
9.3.5 PROBUPHINE
9.3.6 OTHERS
10 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 IMMEDIATE RELEASE
10.3 EXTENDED RELEASE
11 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 SUBLINGUAL FILM
11.2.3 OTHERS
11.3 PARENTERAL
11.3.1 SOLUTION
11.3.2 SUSPENSION
11.4 OTHERS
12 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULTS
12.3 TEENAGE
13 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER
13.1 OVERVIEW
13.2 REHABILITATION CLINICS
13.3 HOSPITALS
13.4 SPECIALTY CENTERS
13.5 HOMECARE
13.6 OTHERS
14 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 DIRECT TENDER
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 FRANCE
15.1.3 U.K.
15.1.4 ITALY
15.1.5 RUSSIA
15.1.6 SPAIN
15.1.7 NETHERLANDS
15.1.8 SWITZERLAND
15.1.9 NORWAY
15.1.10 POLAND
15.1.11 HUNGARY
15.1.12 LITHUANIA
15.1.13 AUSTRIA
15.1.14 IRELAND
15.1.15 TURKEY
15.1.16 REST OF EUROPE
16 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021)
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 INDIVOR PLC (2021)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 VIATRIS INC (2021)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021)
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 ALKERMES (2021)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 PURDUE PHARMA L.P. (2021)
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 PFIZER (2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 GLENMARK PHARMACEUTICAL INC (2021)
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 DR. REDDY’S LABORATORIES LTD (2021)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ALVOGEN (2021)
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS)
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 AMNEAL PHARMACEUTICALS LLC (2021)
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 AMERICAN ADDICTION CENTERS (2021)
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 HIKMA PHARMACEUTICALS PLC (2021)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 LANNETT (2021)
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 MALLINCKRODT (2021)
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021)
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 PINNACLE TREATMENT CENTERS
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 RECOVERY CENTERS OF AMERICA
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
18.21 TAJ PHARMACEUTICALS LIMITED
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 TITAN PHARMACEUTICALS (2021)
18.22.1 COMPANY SNAPSHOT
18.22.2 REVENUE ANALYSIS
18.22.3 PRODUCT PORTFOLIO
18.22.4 RECENT DEVELOPMENTS
18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021))
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 10 EUROPE BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 22 EUROPE IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 31 EUROPE ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 EUROPE REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 40 EUROPE HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 EUROPE OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 46 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 EUROPE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 EUROPE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 53 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 54 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 55 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 56 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 57 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 58 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 59 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 60 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 GERMANY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 GERMANY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 GERMANY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 GERMANY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 GERMANY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 69 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 70 GERMANY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 72 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 73 GERMANY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 74 GERMANY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 75 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 76 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 FRANCE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 FRANCE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 FRANCE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 FRANCE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 FRANCE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 85 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 86 FRANCE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 87 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 88 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 FRANCE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 FRANCE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 92 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 U.K. MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 U.K. OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.K. ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.K. OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.K. THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 101 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 102 U.K. BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 103 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 104 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 105 U.K. ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 U.K. PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 108 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 ITALY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 ITALY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 ITALY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 ITALY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 ITALY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 117 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 118 ITALY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 119 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 120 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 121 ITALY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 122 ITALY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 123 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 124 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 125 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 126 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 RUSSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 RUSSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 RUSSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 RUSSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 RUSSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 133 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 134 RUSSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 135 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 136 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 137 RUSSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 138 RUSSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 139 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 140 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 141 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 142 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 SPAIN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SPAIN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 SPAIN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 SPAIN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 SPAIN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 149 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 150 SPAIN BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 151 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 152 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 153 SPAIN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 154 SPAIN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 155 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 156 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 158 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 NETHERLANDS MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 NETHERLANDS OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 NETHERLANDS ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 NETHERLANDS OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 NETHERLANDS THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 165 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 166 NETHERLANDS BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 167 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 168 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 169 NETHERLANDS ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 170 NETHERLANDS PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 171 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 172 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 173 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 174 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 SWITZERLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SWITZERLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 SWITZERLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SWITZERLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 SWITZERLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 181 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 182 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 183 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 184 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 185 SWITZERLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 186 SWITZERLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 187 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 188 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 189 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 190 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 NORWAY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 NORWAY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 NORWAY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 NORWAY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 NORWAY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 197 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 198 NORWAY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 199 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 200 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 201 NORWAY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 202 NORWAY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 203 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 204 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 POLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 POLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 POLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 POLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 211 POLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 213 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 214 POLAND BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 215 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 216 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 217 POLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 218 POLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 219 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 220 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 221 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 222 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 HUNGARY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 HUNGARY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 HUNGARY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 226 HUNGARY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 227 HUNGARY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 229 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 230 HUNGARY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 231 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 232 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 233 HUNGARY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 234 HUNGARY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 235 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 236 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 237 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 238 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 LITHUANIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 240 LITHUANIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 LITHUANIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 LITHUANIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 LITHUANIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 245 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 246 LITHUANIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 247 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 248 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 249 LITHUANIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 250 LITHUANIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 251 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 252 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 253 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 254 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 255 AUSTRIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 256 AUSTRIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 AUSTRIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 258 AUSTRIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 259 AUSTRIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 261 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 262 AUSTRIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 263 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 264 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 265 AUSTRIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 266 AUSTRIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 267 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 268 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 269 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 270 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 IRELAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 IRELAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 273 IRELAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 IRELAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 275 IRELAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 276 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 277 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 278 IRELAND BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 279 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 280 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 281 IRELAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 282 IRELAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 283 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 284 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 285 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 286 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 287 TURKEY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 TURKEY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 TURKEY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 TURKEY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 TURKEY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 292 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 293 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 294 TURKEY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 295 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 296 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 297 TURKEY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 298 TURKEY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 299 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 300 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 301 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 302 REST OF EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION
FIGURE 2 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029
FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET
FIGURE 15 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019
FIGURE 16 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021
FIGURE 17 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021
FIGURE 21 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029)
FIGURE 23 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE
FIGURE 24 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021
FIGURE 25 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021
FIGURE 29 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)
FIGURE 30 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 33 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 34 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 35 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021
FIGURE 37 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 38 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 39 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021
FIGURE 41 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 42 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 46 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 49 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 50 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 53 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
